



23 September 2019

Australian Securities Exchange
20 Bridge Street,
Sydney NSW 2000

Director's Interest Notice – Correction

Melbourne, Victoria – Alcidion Group Limited (ASX:ALC) (**Company**) advises that the attached Appendix 3Y – Change in Director Interest Notice replaces the notice for Ms K Doyle, known as Kate Quirke, previously lodged with the ASX on 29 April 2019.

The previous Director Interest Notices have incorrectly excluded the interests of MKMS Investment Pty Ltd ATF MKMS Investment Trust (**MKMS**) and Robin Michael Doyle ATF The Doyle Super Fund (**RMD**), Ms Doyle's husband's super fund.

Shares were allotted to MKMS as a result of the Company's acquisition of Patienttrack Holdings Limited with some shares issued immediately, but the majority held in escrow until 3 July 2019.

The interests of MKMS and RMD were inadvertently excluded on Ms Doyle's Appendix 3X lodged with the ASX on 3 July 2018. Since that time there has been no change in the holdings of RMD. The shares issued on 3 July 2018 to MKMS that were not subject to escrow, were subsequently distributed to individual unit holders, including 144,002 shares to Ms Doyle as reported in the Appendix 3Y lodged on 19 October 2018.

The corrected Appendix 3Y of 29 April 2019 is attached.

ENDS

For further information, please contact:

Kyahn Williamson,
WE Buchan
Ph: 0401018828
kwilliamson@we-buchan.com

About Alcidion

Alcidion Limited (ASX:ALC) has a simple purpose: to transform healthcare with smart, intuitive technology solutions that meet the needs of hospital and allied healthcare, worldwide. It offers a complementary set of software products and services that create a unique offering in the global healthcare market; solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient outcomes. In 2017 Alcidion acquired Oncall System and its Smartpage clinical communication system. In 2018 it acquired the Patienttrack bedside patient monitoring software and MKM Health, an IT solutions and services provider. These offerings now operate under the Alcidion brand. With over 25 years of combined healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2019. Alcidion, MKM Health, Miya, Patienttrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

info@alcidion.com
www.alcidion.com
+61 3 8060 6Z077

Level 10/9 Yarra Street
South Yarra VIC 3141
Australia

ABN 77 143 142 410

Appendix 3Y

Change of Director's Interest Notice - Correction

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ALCIDION GROUP LIMITED
ABN	77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Katrina Elizabeth Doyle (aka Kate Quirke)
Date of last notice	4 December 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<p>MNMD Pty Ltd <Quirke Superannuation Fund> (Sole Director and Beneficiary) (MNMD)</p> <p>MKMS Investment Pty Ltd <MKMS Investment Trust> (Director and Unit Holder) (MKMS)</p> <p>Robin Michael Doyle <The Doyle Super Fund> (Joint Trustee) (RMD)</p>
Date of change	26 April 2019
No. of securities held prior to change	<p>Direct 19,893,428 Fully Paid Ordinary Shares</p> <p>Indirect 11,262,919 Fully Paid Ordinary Shares (MNMD) 100,000 Fully Paid Ordinary Shares (RMD) 7,885,463 Fully Paid Ordinary Shares (MKMS)</p>
Class	Fully Paid Ordinary Shares
Number acquired	2,000,000
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$165,400.00

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	Direct 19,893,428 Fully Paid Ordinary Shares Indirect 13,262,919 Fully Paid Ordinary Shares (MNMD) 100,000 Fully Paid Ordinary Shares (RMD) 7,885,463 Fully Paid Ordinary Shares (MKMS)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.